Lourdes Estevez
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by GSK at 31.1% of the total. Reporting peaked in 2022 at $1,969 and has fallen 78.0% since, to $433 in 2025. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $27.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Boehringer Ingelheim$973
- Sanofi$590
- AstraZeneca$524
- Actelion Pharmaceuticals US, Inc.$459
- Mallinckrodt Hospital Products Inc.$370
- plus $1K from 22 others
What the payments were for
- Food & beverage$6,400100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 63 | $1,993 |
| Boehringer Ingelheim | 33 | $973 |
| Sanofi | 17 | $590 |
| AstraZeneca | 17 | $524 |
| Actelion Pharmaceuticals US, Inc. | 22 | $459 |
| Mallinckrodt Hospital Products Inc. | 18 | $370 |
| Insmed, Inc. | 9 | $240 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $216 |
| Regeneron Healthcare Solutions, Inc. | 6 | $188 |
| United Therapeutics Corporation | 5 | $129 |
| Baxter Healthcare | 6 | $126 |
| Mylan Specialty L.p. | 4 | $91 |
| Paratek Pharmaceuticals, Inc. | 3 | $65 |
| Amgen | 3 | $56 |
| Johnson & Johnson | 3 | $51 |
| Advanced Respiratory, Inc | 2 | $44 |
| Bayer | 2 | $44 |
| Inogen, Inc. | 1 | $35 |
| Merck | 1 | $33 |
| Novo Nordisk | 2 | $31 |
| Vifor Pharma, Inc. | 1 | $28 |
| Verona Pharma, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Medtronic | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
| Pinnacle Biologics, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$373
- FASENRA$229
- TRELEGY ELLIPTA$125
- DUPIXENT$124
- OFEV$103
How this compares
$6,400 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 450 | $308,506 |
| Breo ElliptaFluticasone/Vilanterol | 138 | $57,669 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $30,594 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $20,834 |
| SymbicortBudesonide/Formoterol Fumarate | 78 | $20,371 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 310 | $7,377 |
| Arnuity ElliptaFluticasone Furoate | 18 | $6,514 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 46 | $4,042 |
| Wixela InhubFluticasone Propion/Salmeterol | 44 | $2,798 |
| Azelastine Hcl | 116 | $2,693 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $2,472 |
| Fluticasone Propionate | 149 | $2,172 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,095 |
| Ventolin HfaAlbuterol Sulfate | 19 | $1,040 |
| Doxycycline Hyclate | 55 | $467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,993 | $393,523639 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $524 | $50,965121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Miami
- Patrick SzarazMiami$327K
- Yamila MelendezMiami$212K
- Suzan RosenMiami$129K
- Felipe NovoaMiami$110K
- Pamela DudkiewiczMiami$89K
- Stacy FeemsterMiami$51K
- Estrella Moreno RodriguezMiami$30K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.